Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

628
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
628
Tumor Immunotherapy01:27

Tumor Immunotherapy

876
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
876
Vaccinations01:51

Vaccinations

49.3K
Overview
49.3K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

80.2K
Overview
80.2K
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

15.2K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
15.2K
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

7.5K
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
7.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cross-Presentation and Activation of CD8+ T Cells: The Role of Pannexin-1 in Dendritic Cells.

International journal of molecular sciences·2026
Same author

Effects of the Sociopolitical Climate on Distress and Relocation of Families of Transgender Youth.

Transgender health·2026
Same author

Management of Severe Cavovarus and Equinocavovarus Deformities Using Hexapod External Fixation.

Foot and ankle clinics·2026
Same author

Lymphodepleting preconditioning impairs host antitumor immunity induced by adoptive T cell therapy in mouse models.

Nature communications·2026
Same author

<i>Lactococcus lactis</i> as a New Strategy for Oral Vaccination: Current Insights and Future Perspectives.

Pharmaceutics·2026
Same author

A <i>KCNC1</i> variant linked to Rett syndrome disrupts ER to Golgi trafficking of Kv3.1 channel.

Proceedings of the National Academy of Sciences of the United States of America·2026

Related Experiment Video

Updated: Nov 23, 2025

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

9.5K

Adenosine triphosphate, polymyxin B and B16 cell-derived immunization induce anticancer response.

Carlos Barrera-Avalos1,2, Javier Mena1, Ximena López1

  • 1Departamento de Biología, Facultad de Química y Biología, Universidad de Santiago de Chile, USACH, Alameda 3363, Santiago, Chile.

Immunotherapy
|January 5, 2021
PubMed
Summary

Whole dead tumor cells, known as B16-immunogenic cell bodies (ICBs), combined with ATP and polymyxin B (PMB), effectively induce an antitumor immune response. This novel vaccine strategy shows significant potential in delaying tumor growth and achieving tumor-free outcomes.

Keywords:
ATPDAMPsanticancercost-effectiveimmunotherapymelanomapolymyxin B

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.5K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.7K

Related Experiment Videos

Last Updated: Nov 23, 2025

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

9.5K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.5K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.7K

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Whole dead tumor cells can serve as antigen sources for cancer vaccines.
  • Damage-associated molecular patterns can enhance the induction of protective immune responses.

Purpose of the Study:

  • To evaluate the in vivo antitumor effect of B16-immunogenic cell bodies (ICBs) combined with ATP and polymyxin B (PMB).

Main Methods:

  • B16 melanoma cells were processed into ICBs via nutrient starvation.
  • The antitumor efficacy of B16-ICBs + ATP + PMB was assessed in a prophylactic immunization model.
  • Immune cell responses, including dendritic cell maturation and T CD8+ lymphocyte activation, were analyzed in vitro.

Main Results:

  • Subcutaneous immunization with B16-ICBs + PMB + ATP resulted in 50% tumor-free animals.
  • This combination therapy significantly delayed tumor growth in a prophylactic approach.
  • Results correlated with enhanced dendritic cell maturation and T CD8+ lymphocyte activation.

Conclusions:

  • The combination of ICBs + ATP + PMB demonstrates efficiency in inducing antitumor efficacy.
  • This approach enhances the vaccine potential of whole dead tumor cells.
  • ICB-based vaccines represent a promising strategy for cancer immunotherapy.